For this purpose, we first established an in vitro exposure model of ECs with uremic serum samples obtained from chronic HD patients during the PERCI-II-MCO trial (Figures 2B–G), employing VEGF expression and production as markers for endothelial activation and endothelial tube formation as a functional readout. Here, VEGFA is linked to Huntington disease.